Last updated: May 30, 2026
Lipitor (atorvastatin) Suppliers: APIs, Key Excipients, and Manufacturing Partners by Supply-Chain Node
Lipitor is sold in the US by Pfizer, but the supply chain for atorvastatin tablets spans (1) active pharmaceutical ingredient (API) manufacturers, (2) excipient and tablet-compression supply, and (3) finished-dose contract manufacturers for specific strengths and packages. A complete, audit-ready supplier map requires current, product-specific data from Pfizer’s commercial dossiers, FDA drug-label/CGMP supply-chain disclosures, and bid documents tied to the NDCs. Without that NDC-level linkage, supplier identification cannot be completed accurately.
Who supplies the atorvastatin API used to make Lipitor?
Featured snippet answer: Atorvastatin API is manufactured by specialized small-molecule API producers under CGMP, then supplied to finished-dose manufacturers and packagers. For Lipitor, Pfizer typically uses a qualified supplier network for both API and intermediates, but Lipitor’s exact API source can differ by batch, strength, and market.
What are the API supply-chain nodes for atorvastatin tablets
- Atorvastatin synthesis intermediates (multiple chemical steps before API crystallization)
- Final API manufacture with defined polymorph/spec specifications
- API packaging and labeling for cGMP traceability
- Release testing (identity, assay, impurity profile, moisture, particle size where applicable)
Which supplier categories matter most for risk
- API and intermediate suppliers with tight impurity control (key for statins due to process-dependent impurity burdens)
- Manufacturers with validated routes to ensure consistent impurity profiles across scale changes
- Suppliers with stable polymorph control and batch-to-batch consistency
Which excipients and formulation-material suppliers support Lipitor tablets?
Featured snippet answer: Lipitor tablet supply depends on excipient suppliers for coating systems, tablet binders/disintegrants, and film-coating pigments. Excipients are typically commodity-to-specialty inputs sourced from qualified distributors and excipient manufacturers, with grade controlled by pharmacopeia and Pfizer specification.
Common excipient classes in atorvastatin oral tablets
- Tablet core: fillers, binders, disintegrants, lubricants
- Film coat: polymer system, plasticizer, pigments/colorants, anti-tacking agent
- Packaging and labeling components: desiccant, bottle components, induction seals
What to diligence for supplier qualification
- Supplier change control and traceability
- Compliance with pharmacopeial specs for each excipient grade
- Supply continuity and contamination controls (especially cross-contamination controls for allergens and manufacturing lines)
Who manufactures and bottles finished-dose Lipitor tablets under contract?
Featured snippet answer: Pfizer can manufacture internally and also uses contract manufacturing and packaging organizations (CMOs/packagers). The specific CMO for a given Lipitor NDC depends on strength, package configuration, and production campaign.
Finished-dose supply chain steps
- Tablet compression and coating line manufacturing
- In-process controls and final release testing
- Primary packaging (bottles/blisters depending on NDC)
- Secondary packaging and distribution release
Which supply-side variables drive CMO selection
- Capacity for high-volume statin tablet production
- Ability to meet coating uniformity and dissolution specifications
- QA systems for change control and comparability studies
What sources of truth identify Lipitor suppliers by NDC?
Featured snippet answer: The most reliable supplier attribution is NDC-linked and can be derived from FDA-facing product listings and label-linked manufacturing sites, plus CGMP dossier references. Without those NDC-linked manufacturing-site mappings, naming specific API or excipient suppliers for “Lipitor” as a whole is not defensible.
Data artifacts that typically disclose manufacturing geography
- FDA label manufacturing/distribution sections listing manufacturer and packager for each strength/NDC
- Submission-linked manufacturing site listings used in NDA/ANDA supplements
- Public FDA product listings that show firm names tied to packaging and labeling
How do generic Lipitor and Authorized-Generic supply networks compare?
Featured snippet answer: Generics and authorized generics generally rely on different API and finished-dose partners than Pfizer’s internal or CMO network. API supply may overlap across markets, but finished-dose manufacturers and packagers differ.
Why comparison matters
- If your goal is supplier benchmarking, you need to compare at the NDC level.
- API source can be common across competitors even when the final tablet manufacturer is different.
What supplier risks matter for atorvastatin continuity (API and finished dose)?
Featured snippet answer: Statin supply risk is driven by API batch continuity, impurity specification drift, and coating/dissolution performance. These risks show up during scale-up, supplier transitions, and regulatory filing updates.
High-impact risk events to diligence
- API impurity excursions after process changes
- Polymorph/crystal habit shifts in API crystallization
- Coating failures impacting dissolution and appearance
- Packaging component shortages affecting market availability
Can you list specific supplier companies for Lipitor’s API and finished dose?
A complete and accurate list of specific suppliers for Lipitor’s API, excipients, and finished-dose manufacturing cannot be produced from the information provided. Naming firms without NDC-linked manufacturing-site mapping or current product-specific source data would create an unreliable supplier roster.
Key Takeaways
- Lipitor supply is multi-tier: atorvastatin API manufacturers, excipient/coating material suppliers, and finished-dose CMOs/packagers.
- Supplier attribution must be NDC-specific to be defensible; Lipitor can use different partners by strength, package, and production campaign.
- For due diligence and RFP-level supplier onboarding, prioritize API impurity control capability, polymorph/crystallization consistency, and coating/dissolution performance plus traceability.
FAQs
- How can I identify the manufacturer for a specific Lipitor NDC?
- What CGMP change-control documents are most relevant when qualifying a new atorvastatin API supplier?
- Which quality attributes of atorvastatin API most often drive supplier-related regulatory findings?
- How does finished-dose coating composition affect dissolution performance for atorvastatin tablets?
- What supplier continuity risks apply to high-volume statin tablet production during global disruptions?
References
- FDA. Drugs@FDA. (US). https://www.accessdata.fda.gov/scripts/cder/daf/
- FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/
